Switching to or from Jatenzo: Protocols, Timing, and Lab Monitoring

Jatenzo (oral testosterone undecanoate) is an FDA-approved oral testosterone replacement therapy (TRT) for men with hypogonadism, taken twice daily with food. It is a distinct formulation from injectable testosterone cypionate or enanthate, transdermal gels and patches (AndroGel, Testim, Androderm), the long-acting injectable Aveed, and newer oral competitors (Tlando, KYZATREX). The useful question when switching is not "how long is the washout" but which formulation is being replaced and how quickly its serum testosterone declines, because that decay curve, not a fixed calendar rule, determines when the next formulation should start and when the first follow-up lab should be drawn.

There is no FDA-labeled crossover protocol for switching between testosterone formulations. Everything below about timing a switch is standard clinical pharmacology reasoning and common prescribing practice, not an instruction printed on any product label. Your prescriber will individualize the plan based on your labs, symptoms, and medical history. This article does not provide a personal dosing recommendation.

The direct answer

Jatenzo is absorbed through the intestinal lymphatic system rather than the portal vein, which is why the FDA label requires dosing with a fat-containing meal. Because Jatenzo has no tissue depot, switching onto or off of it does not require a fixed washout period; instead, the timing follows the pharmacokinetics of whichever formulation is being replaced (short-acting esters clear over roughly one to two weeks, long-acting Aveed persists for weeks to months, gels and patches clear within about a day). Whatever the direction of the switch, a follow-up testosterone level drawn at the correct time relative to the most recent dose, not an arbitrary trough, is what prevents an unnecessary dose change.

How Jatenzo's absorption differs from other formulations

Jatenzo uses a self-emulsifying drug delivery system that carries testosterone undecanoate into the intestinal lymphatic circulation, largely bypassing first-pass liver metabolism. This is described in the FDA-approved prescribing information for Jatenzo. Peak serum testosterone after an oral dose occurs several hours later and then declines before the next dose, a twice-daily rhythm that looks nothing like the multi-day decay curve of an injectable ester or the steady-state plateau of a daily topical gel.

The FDA label instructs patients to take Jatenzo with a meal, and dietary fat is understood to materially affect absorption of lymphatically-transported drugs of this type. Patients who take the capsule fasting or with a very low-fat meal may show a lower-than-expected testosterone level after a switch, and this can be mistaken for treatment failure rather than a dosing-conditions problem. Confirming meal timing and fat content is a reasonable first troubleshooting step before changing the dose.

A note on efficacy and safety percentages. An earlier version of this content cited specific figures (percentage of patients reaching target testosterone, hematocrit and lipid changes, exact blood pressure increases) attributed to the Jatenzo clinical trial and to specific PubMed identifiers. Those identifiers could not be verified against the primary literature during this review, and reproducing precise numbers without a confirmed source risks stating false precision on a prescribing decision. The general direction of these effects (testosterone-driven erythrocytosis, a boxed warning for blood pressure, and label-required lipid and PSA monitoring) is consistent with what is known about testosterone therapy as a class, but exact trial percentages for Jatenzo specifically should be confirmed against the current FDA label before being used in patient-facing material.

Why patients switch formulations

Common reasons include skin irritation or transfer risk with topical gels, needle aversion or injection-site discomfort with cypionate or enanthate, difficulty with the twice-daily-with-food schedule required by oral formulations, insurance formulary changes, and a preference to avoid the household transfer risk that comes with transdermal products. The Endocrine Society's 2018 clinical practice guideline on testosterone therapy addresses secondary exposure risk with topical formulations and general monitoring principles for TRT; a specific quotation from that guideline is not reproduced here because it could not be verified against the primary document during this revision, and an unverifiable direct quote is a greater risk than a plain paraphrase.

Switching from injectable cypionate or enanthate to Jatenzo

Testosterone cypionate and enanthate have elimination half-lives of roughly a week, and serum testosterone declines gradually over the one to two weeks after an injection. In common clinical practice:

• If the last injection was recent (within the interval where the depot is still active), Jatenzo is typically started on the day the next injection would have been due, without a separate washout period, since the residual depot is already declining as oral absorption ramps up.
• If more than two weeks have passed since the last injection, the depot is largely depleted and starting Jatenzo without further delay is reasonable to avoid a symptomatic gap.
• Aveed (testosterone undecanoate injection) behaves very differently because of its much longer dosing interval. Switching from Aveed to Jatenzo generally means waiting several weeks after the last Aveed injection before starting oral dosing, given its prolonged depot effect, with earlier lab follow-up to catch any overlap.

A serum total testosterone drawn several weeks after starting Jatenzo, timed a few hours after a morning dose taken with food, is the standard way to check whether the starting dose is appropriate. This is a clinical judgment applied individually; it is not a fixed formula.

Switching from topical gel or patch to Jatenzo

Topical testosterone and patches reach steady state within a few days and clear from the system within about a day of stopping. Because there is no depot effect, the crossover is more straightforward than with injections: stop the topical product, then begin Jatenzo with the next fat-containing meal. Some patients notice a brief dip in energy as the last topical dose clears before oral absorption ramps up; if this occurs it typically resolves within one to two days. The same same-day logic applies to switching from intranasal testosterone (Natesto), which also has no meaningful carryover effect the following day.

Switching from Jatenzo to injectable or topical TRT

Jatenzo clears rapidly, with serum testosterone returning toward baseline hypogonadal levels within roughly a day or two of the last dose. When moving to an injectable, the first injection is commonly given the day after the last Jatenzo dose, since there is no oral depot to overlap with. When moving to a topical gel, the first application is commonly made the morning after the last Jatenzo dose. When moving to Aveed, the loading protocol on that product's label applies, and Aveed carries a REMS requirement for in-office monitoring after each injection because of a rare post-injection pulmonary oil microembolism reaction; this observation requirement is a label requirement, not a switching-specific add-on.

Lab monitoring after any formulation switch

The general principle across testosterone therapy is that the follow-up lab should be timed to the pharmacokinetics of the new formulation: roughly midway between doses for injectables, a few hours after application for topical products, and a few hours after a morning dose for Jatenzo. A trough level drawn immediately before a Jatenzo dose will read low and does not reflect true exposure; it can lead to an unnecessary dose increase if a clinician is not aware of the oral formulation's twice-daily curve.

Independent of the target testosterone level, the following should be checked after any TRT formulation change, generally in the two- to three-month range, per standard testosterone-therapy monitoring practice:

• Hematocrit. Testosterone-driven erythrocytosis is a class effect across all delivery methods. Switching formulations does not reset an already elevated hematocrit, and does not eliminate the ongoing need to monitor it.
• PSA. A baseline and follow-up PSA is standard practice for men on testosterone therapy, particularly in older men, independent of which formulation is used.
• Lipids. Oral testosterone undecanoate's effect on HDL cholesterol relative to injectable or topical testosterone has been described in the literature, though the exact magnitude reported for Jatenzo specifically needs to be confirmed against the current label rather than repeated from an unverified figure.
• Blood pressure. The Jatenzo label carries a boxed warning regarding blood pressure increases. Home blood pressure monitoring for the first several weeks after starting or switching to Jatenzo is a reasonable precaution, particularly in patients with any baseline hypertension.

Dose titration after switching

Jatenzo is available in three capsule strengths, all dosed twice daily. The FDA-labeled starting dose applies to new Jatenzo starts regardless of the prior formulation or its dose, because oral bioavailability depends on individual lymphatic absorption and dietary fat intake rather than on the previous drug's dose. If a follow-up level is above the target range, the dose is typically stepped down; if it remains below target on the highest labeled dose with confirmed adequate fat intake, some men are simply poor lymphatic absorbers of this delivery system, and a different formulation may be more appropriate than further titration.

The Endocrine Society's 2018 guideline predates Jatenzo's approval and does not contain oral-testosterone-undecanoate-specific titration guidance. In its absence, clinicians generally follow the FDA label's titration algorithm for this drug specifically.

Special populations

• Older men. Data on Jatenzo in men over 65 is limited relative to younger cohorts studied in its approval trials. The blood pressure warning deserves particular attention here given the high background prevalence of hypertension in older men, as documented by CDC surveillance data on blood pressure (accessed 2026; check for updated figures before citing a specific prevalence number).
• Cardiovascular risk. Current guideline-level caution advises against initiating testosterone therapy, including via a formulation switch, in men with a recent major cardiovascular event. This is a guideline recommendation, not a Jatenzo-specific label restriction, and should be discussed directly with a prescriber.
• Hepatic impairment. Because Jatenzo's lymphatic absorption route bypasses first-pass liver metabolism, it is sometimes discussed as a potential option for patients with mild hepatic impairment or fatty liver disease, in contrast to older oral methyltestosterone products associated with hepatotoxicity. This is a plausible mechanistic argument, not a demonstrated outcome from a hepatic-impairment trial, and should not be treated as an established safety claim.
• Anticoagulant use. Testosterone therapy can potentiate warfarin. Because a formulation switch can change the pharmacokinetic pattern of testosterone exposure, rechecking INR in the weeks after any switch is a reasonable precaution regardless of which direction the switch goes.

Insurance and cost considerations

Jatenzo is a branded specialty product, and many commercial insurers require prior authorization, often with step therapy through a generic injectable or topical product first. Documenting the clinical reason for a requested switch (skin reaction, transfer risk, injection intolerance) is standard practice for a prior authorization request. Generic oral testosterone undecanoate products (Tlando, KYZATREX) have entered the market as alternatives; pricing varies by pharmacy and plan and should be checked directly rather than assumed, since list prices and copay program terms change over time.

Evidence boundary: what is established and what is not

Established: Jatenzo's lymphatic absorption mechanism and its FDA-required food requirement; the general half-life patterns of testosterone esters and the resulting shape of their decline curves; the existence of an FDA boxed warning on blood pressure for Jatenzo; the class-wide association between testosterone therapy and erythrocytosis; and the general principle that testosterone levels should be drawn at a time matched to the formulation's pharmacokinetics.

Plausible but not confirmed in this review: exact percentages of patients reaching target testosterone on Jatenzo, exact magnitude of HDL or blood pressure change attributable to Jatenzo specifically, and hepatic-impairment safety data, all of which require confirmation against the current FDA label or a verified primary trial report before being stated as fact.

Not established: any universal "correct" washout interval for every formulation pair. Practice varies by clinician and patient, and no professional guideline currently specifies formulation-switch timing as precisely as the older version of this content implied.

Clinician conversation and monitoring framework for a formulation switch

Use this as a discussion checklist with a prescriber, not as a self-directed protocol.

Before switching, confirm:

1. The specific reason for the switch (side effect, cost, adherence, transfer risk) and whether it changes the urgency of the timeline.
2. The exact formulation and last dose date/time of the current therapy, since this determines the expected decay curve.
3. Any cardiovascular event history in the past 6 months, current blood pressure control, and anticoagulant use.
4. Baseline hematocrit, PSA, and lipid panel if not drawn within the past 6 to 12 months.

Timing checkpoints:

• Day of switch: based on the outgoing formulation's expected decline (same day for short-acting injectables near their next dose, next morning for gels/patches/nasal, several weeks out for Aveed).
• 2 to 4 weeks after starting Jatenzo: testosterone level drawn a few hours after a morning dose taken with food, not a pre-dose trough.
• 6 to 12 weeks: hematocrit, repeat blood pressure check, and lipid recheck if baseline was abnormal or the patient has cardiovascular risk factors.
• 3 to 6 months: PSA recheck, symptom review, and reassessment of whether the current dose and formulation are meeting the patient's goals.

Stop or escalate if:

• Hematocrit rises above the threshold your prescriber has set as unsafe (commonly discussed around the mid-50s percent range, but this is an individualized cutoff, not a fixed number to self-apply).
• Blood pressure rises meaningfully and consistently on home monitoring after starting or switching to Jatenzo.
• New or worsening cardiovascular symptoms, sudden vision changes, leg swelling, or shortness of breath occur, which warrant urgent evaluation rather than waiting for the next scheduled lab.
• Testosterone remains below target on the highest labeled dose with confirmed adequate fat intake, suggesting the formulation itself may not be a good fit rather than a dose problem.

Where label guidance ends and individualized judgment begins: The FDA label governs starting dose, the food requirement, and the boxed warning monitoring obligations. It does not govern how to time a switch away from or onto another product; that is clinical judgment exercised by your prescriber based on your specific labs, history, and the pharmacology of the formulation you are leaving or joining. Any schedule you find in an article, including this one, should be treated as a starting point for a conversation rather than an instruction to follow independently.

When to seek urgent care

Chest pain, sudden shortness of breath, one-sided weakness or facial drooping, sudden severe headache, or signs of a blood clot (calf swelling and pain, or sudden leg discoloration) after starting or switching any testosterone formulation warrant emergency evaluation rather than a routine follow-up appointment.